




ASO Visual Abstract: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Marco Tonello, MD¹, Dario Baratti, MD², Paolo Sammartino, MD³, Andrea Di Giorgio, MD⁴, Manuela Robella, MD⁵, Cinzia Sassaroli, MD⁶, Massimo Framarini, MD⁷, Mario Valle, MD⁸, Antonio Macrì, MD⁹, Luigina Graziosi, MD¹⁰, Federico Coccolini, MD^{11,14}, Piero Vincenzo Lippolis, MD¹², Roberta Gelmini, MD¹³, Marcello Deraco, MD², Daniele Biacchi, MD³, Francesco Santullo, MD⁴, Marco Vaira, MD⁵, Katia Di Lauro, MD¹⁵, Fabrizio D'Acapito, MD⁷, Fabio Carboni, MD⁸, Giuseppe Giuffrè, MD⁹, Annibale Donini, MD¹⁰, Paola Fugazzola, MD¹¹, Pinuccia Faviana, MD¹⁶, Lorena Sorrentino, MD¹³, Antonio Scapinello, MD¹⁷, Paola Del Bianco¹⁸, and Antonio Sommariva, MD¹

¹Unit of Surgical Oncology of the Esophagus and Digestive Tract, Surgical Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; ²Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Cytoreductive Surgery and HIPEC Unit, Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy; ⁴Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ⁵Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; ⁶Colorectal Surgical Oncology, Abdominal Oncology Department, “Fondazione Giovanni Pascale” IRCCS – Naples, Naples, Italy; ⁷General and Oncologic Surgery, Morgagni –Pierantoni Hospital, AUSL Romagna, Forlì, Italy; ⁸Peritoneal Malignancies Unit, INT “Regina Elena”, Rome, Italy; ⁹Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Messina, Italy; ¹⁰General and Emergency Surgery Department, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy; ¹¹General Emergency and Trauma Surgery, Bufalini Hospital, Cesena, Italy; ¹²General and Peritoneal Surgery, Department of Surgery, Hospital University Pisa (AOUP), Pisa, Italy; ¹³General and Oncological Surgery Unit, AOU of Modena University of Modena and Reggio Emilia, Modena, Italy; ¹⁴General Emergency and Trauma Surgery, Pisa University Hospital, Pisa, Italy; ¹⁵Department of Advanced Biomedical Sciences, “Federico II” University, Naples, Italy; ¹⁶Pathological Anatomy III, Laboratory Medicine Department, Hospital University Pisa (AOUP), Pisa, Italy; ¹⁷Pathology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; ¹⁸Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Surgical treatment of patients affected by colorectal peritoneal metastases leads to remarkable improvement in survival, but selection is crucial. Analysis of 437 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) demonstrated that

KRAS/BRAF mutations are related to reduced survival, whereas microsatellite instability confers survival advantage, even in mutated patients (<http://doi.org/10.1245/s10434-021-11045-3>).



FUNDING This study was not funded and has not been presented elsewhere.

DISCLOSURES Marco Tonello, Dario Baratti, Paolo Sammartino, Andrea Di Giorgio, Manuela Robella, Cinzia Sassaroli, Massimo Framarini, Mario Valle, Antonio Macrì, Luigina Graziosi, Federico Coccolini, Piero Vincenzo Lippolis, Gelmini Roberta, Marcello Deraco, Daniele Biacchi, Francesco Santullo, Marco Vaira, Katia Di Lauro, Fabrizio D'Acapito, Fabio Carboni, Giuseppe Giuffrè,

Annibale Donini, Paola Fugazzola, Pinuccia Faviana, Sorrentino Lorena, Antonio Scapinello, Paola Del Bianco, and Antonio Sommariva have no disclosures or conflicts of interest to declare.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.